The editors of Diabetes Care feel it is our charge to bring to the forefront a contentious topic directly related to the care of people with diabetes: the ongoing debate on the risks versus the benefits of incretin-based therapies. In this online collection, which appears in the July 2013 issue of Diabetes Care, we present five articles providing background material and specific arguments on this controversy.
Signals and Noise in Drug Safety Analyses: The Incretin Therapy Debate Provides the Rationale for Revamping Epidemiologic Pharmacovigilance
William T. Cefalu, MD; Julio Rosenstock, MD; Robert R. Henry, MD; Matthew Riddle, MD
Diabetes Care 2013 Jul; 36 (7): 1804-1806. http://dx.doi.org/10.2337/dc13-0895
Interpreting Adverse Signals in Diabetes Drug Development Programs
Clifford J. Bailey, PhD
Diabetes Care 2013 Jul; 36 (7): 2098-2106. http://dx.doi.org/10.2337/dc13-0182
Assessing the Beneﬁt-Risk for New Drugs: Are the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products In Sync?
Eric P. Brass, MD, PhD
Diabetes Care 2013 Jul; 36 (7): 1823-1826. http://dx.doi.org/10.2337/dc13-0891
A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 Therapies Safe?
Peter C. Butler, MD; Michael Elashoff, PhD; Robert Elashoff, PhD; Edwin A.M. Gale, MD
Diabetes Care 2013 Jul; 36 (7): 2118-2125. http://dx.doi.org/10.2337/dc12-2713
A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The Benefits by Far Outweigh the Potential Risks
Michael A. Nauck, MD, PhD
Diabetes Care 2013 Jul; 36 (7): 2126-2132. http://dx.doi.org/10.2337/dc12-2504